Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women

Inclusion Criteria: * Women at least 5 years after menopause * Maximum intima-media thickness of common carotid artery more than 0,80 mm (ultrasonographic B-mode examination) * The absence of climacteric syndrome (less than 3 points by Blatt-Kupperman scale) * The absence of chronic diseases demanding permanent drug administration (more than 2 month per year) * The absence of hypolipidemic therapy or hormone replacement therapy during 6 months before the inclusion Exclusion Criteria: * Administration of lipid-lowering drugs, and/or hormone replacement therapy, and/or phytoestrogens during 6 month before inclusion * Continuous administration of sulfonylurea derivatives, and/or beta-blockers, and/or calcium antagonists (more than 2 months per year) * Personal history or diagnostic of following diseases: 1. Personal history of stroke, coronary heart disease, acute myocardial infarction or transient ischemic attacks 2. Pulmonary thromboembolism 3. Chronic heart failure IIa-III 4. Uncontrolled arterial hypertension (systolic blood pressure \> 145 mmHg, diastolic blood pressure \> 95 mmHg under hypotensive therapy) 5. Malignancy 6. Chronic renal failure II-III 7. Chronic hepatic failure II-III 8. Liver cirrhosis 9. Individual intolerance of Karinat or major side effects